SciSparc Ltd. (SPRC) stock forecast & analysis
1 analysis in the last 30 days. Latest: .
Market Scanner’s AI analysis of SciSparc Ltd. (SPRC), updated July 2026: SciSparc's quantum platform advancement and Tourette Syndrome trial progress were key recent observations.
Summary
SciSparc's quantum platform advancement and Tourette Syndrome trial progress were key recent observations.
Recent analyses for SciSparc (SPRC) covered the advancement of its quantum platform for clinical data analytics via its subsidiary NeuroThera Labs, including targeting the Agentic AI market. The initiation of a Phase IIb clinical trial for Tourette Syndrome in Germany was also a focus. Technical indicators showed mixed signals with a short-term downtrend and approaching overbought conditions, alongside moderate volatility.
SPRC news & sentiment
Recent news highlighted SciSparc's progress in its quantum platform development and clinical trials, including targeting the Agentic AI market. No social media sentiment was available for the company.
SPRC technical picture
The 50-day SMA was below the 200-day SMA, indicating a medium-term downtrend relative to the long-term trend, while the 10-day EMA suggested a recent short-term downtrend. Momentum indicators showed mixed signals, with the RSI approaching overbought territory and the MACD indicating weakening bullish momentum, while the MFI suggested strong buying pressure. Price action was noted near the upper Bollinger Band, suggesting a resistance zone.
Fundamentals
The company reported declining quarterly revenue and a negative operating margin, with a profit margin of 0%. Valuation metrics such as P/E were available, but forward P/E and dividend yield were not. Return on equity was negative, and historical income statements showed consistent net losses.
Factors discussed — upside
- Money Flow Index (MFI) at a very high 98.12 suggesting strong buying pressure
- Relative Strength Index (RSI) approaching overbought territory
- Advancement of quantum platform for clinical data analytics
- Initiation of Phase IIb clinical trial for Tourette Syndrome
Factors discussed — risks
- 50-day SMA below 200-day SMA indicating a medium-term downtrend
- 10-day EMA suggesting a recent short-term downtrend
- MACD indicating bearish momentum crossover or weakening bullish momentum
- Quarterly Revenue Growth (Year-over-Year) of -34.5%
- Consistent net losses in historical income statements
- Clinical trial progress
- Quantum platform development
- Technical indicators
- Financial performance
Summary updated .
Analyses
Recent SPRC.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for SciSparc Ltd.?
- The bull case centers on strong buying pressure indicated by a high Money Flow Index, with the Relative Strength Index approaching overbought territory. Progress in advancing the quantum platform for clinical data analytics and the initiation of a Phase IIb clinical trial for Tourette Syndrome were highlighted as key developments.
- What are the risks for SciSparc Ltd.?
- Risks discussed include a medium-term downtrend indicated by moving averages, with short-term momentum weakening. A significant year-over-year revenue decline and consistent historical net losses were also noted, alongside the stock's high beta suggesting increased volatility.
- Is SciSparc Ltd. bullish or bearish?
- Recent AI analyses of SciSparc Ltd. examined factors on both sides. Discussed upside: The bull case centers on strong buying pressure indicated by a high Money Flow Index, with the Relative Strength Index approaching overbought territory. Progress in advancing the quantum platform for clinical data analytics and the initiation of a Phase IIb clinical trial for Tourette Syndrome were highlighted as key developments. Discussed risks: Risks discussed include a medium-term downtrend indicated by moving averages, with short-term momentum weakening. A significant year-over-year revenue decline and consistent historical net losses were also noted, alongside the stock's high beta suggesting increased volatility. These are descriptive observations, not a recommendation.
- What is the latest sentiment on SciSparc Ltd.?
- Recent news highlighted SciSparc's progress in its quantum platform development and clinical trials, including targeting the Agentic AI market. No social media sentiment was available for the company.
- Bundles used
- gemini-low-v2
Sign in to read every SPRC.US report in the library
Each analysis includes the full reasoning, dissent, and decision rationale from the structured AI pipeline.